Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM AMINOSALICYLATE vs NYDRAZID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.
Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.
Adjunctive treatment of tuberculosis (as second-line agent),Off-label: treatment of ulcerative colitis (as mesalamine prodrug)
Treatment of active tuberculosis (in combination with other antituberculous agents),Prophylaxis of tuberculosis in high-risk individuals
Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.
300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.
0.5-1.5 hours for parent drug; acetylated metabolite half-life 2-3 hours; accumulation occurs in renal impairment.
Terminal elimination half-life: 1-4 hours (fast acetylators), 2-8 hours (slow acetylators). Half-life prolonged in hepatic impairment; adjust dose.
Hepatic (acetylation to N-acetyl-4-aminosalicylic acid and other metabolites); also undergoes intestinal metabolism by gut bacteria.
Hepatic metabolism primarily via N-acetyltransferase 2 (NAT2) to acetylisoniazid, which is further metabolized to hepatotoxic metabolites.
Renal: >80% as metabolites (acetyl, glycolyl conjugates) and unchanged drug; fecal: <5%.
Renal excretion of unchanged drug and metabolites; 50-70% excreted in urine within 24 hours, mainly as acetylisoniazid and isonicotinic acid. Biliary/fecal: <10%.
50-60% bound to albumin.
10-20% bound primarily to albumin; binding is low and clinically insignificant.
0.2-0.4 L/kg; reflects distribution into total body water with limited tissue penetration.
Vd: 0.6-0.8 L/kg; distributes into total body water, including CSF, pleural fluid, and caseous granulomas.
Oral: ~90% absorbed; food may delay absorption.
Oral: 90-100% (fasting). Food may decrease absorption by 20-50%; take on empty stomach.
GFR <50 m L/min: not recommended due to risk of accumulation; if unavoidable, reduce dose to 4 g once daily. GFR <30 m L/min: avoid use.
If GFR < 30 m L/min: administer 200 mg once daily or 300 mg three times weekly. For severe renal impairment (GFR < 10 m L/min) or hemodialysis: 200 mg daily or 300 mg three times weekly, given after dialysis.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% (to 2 g twice daily). Child-Pugh Class C: avoid use.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50% (e.g., 150 mg daily). Child-Pugh Class C: reduce dose by 50-75% (e.g., 100-150 mg daily) or consider alternative therapy; monitor liver function closely.
Children: 200-300 mg aminosalicylic acid base per kg body weight per day, divided into 2 doses. Maximum 8 g/day.
For latent tuberculosis: 10-15 mg/kg (max 300 mg) orally once daily for 6-9 months. For active tuberculosis: 10-15 mg/kg (max 300 mg) orally once daily for 2 months, then 15 mg/kg (max 900 mg) orally three times weekly for 4-7 months.
Start at lower end of dosing (4 g once daily) due to potential decreased renal function and increased risk of gastrointestinal intolerance.
Start at lower end of dosing range (e.g., 200-300 mg daily) due to potential renal impairment; monitor liver function and signs of hepatotoxicity; adjust dose based on creatinine clearance if GFR < 30 m L/min.
No FDA black box warning.
Severe and sometimes fatal hepatitis has been reported, even after months of treatment. Risk increases with age, daily alcohol use, and pre-existing liver disease. Monitor liver function tests closely.
Hypersensitivity reactions including fever and rash,Hepatotoxicity (discontinue if jaundice or liver enzyme elevation occurs),Renal impairment may require dose adjustment,Gastrointestinal intolerance,May cause hypocalcemia and hypokalemia,Interference with thyroid function tests
Peripheral neuropathy (prevent with pyridoxine), hepatotoxicity, hypersensitivity reactions (e.g., fever, rash), lupus-like syndrome, seizures, optic neuritis, drug interactions (e.g., phenytoin, carbamazepine, disulfiram).
Hypersensitivity to any salicylate component,Severe hepatic disease,Severe renal impairment (e GFR < 30 m L/min)
Severe hepatic disease, acute liver disease, or previous isoniazid-associated hepatitis; hypersensitivity to isoniazid or any component.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid large amounts of high-potassium foods (e.g., bananas, oranges, potatoes) unless directed by a physician, as this drug may alter potassium levels. No specific food restrictions beyond these.
Isoniazid inhibits monoamine oxidase (MAO) and reduces metabolism of tyramine, leading to hypertensive crisis. Avoid tyramine-rich foods: aged cheeses (cheddar, blue cheese), cured or fermented meats (salami, pepperoni, pickled herring), soy products (tofu, miso, tempeh), sauerkraut, fava beans, tap beers, and red wines. Also avoid foods containing histamine (tuna, mackerel, sauerkraut). Concomitant alcohol consumption increases risk of hepatotoxicity and should be strictly avoided. High-protein meals or dairy may interfere with absorption; maintain consistent timing relative to meals. There is no restriction on carbohydrates or fats.
First trimester: Insufficient data; no known human teratogenicity but animal studies inconclusive. Second/third trimester: No documented fetal harm; use only if clearly needed.
Isoniazid (INH) is not associated with major congenital malformations in humans. However, in vivo animal studies have shown embryocidal effects at high doses. The drug is considered safe during all trimesters; however, due to the risk of hepatotoxicity, monitoring of liver function is recommended, especially in the third trimester. Perinatal exposure increases the risk of neonatal hemorrhage due to vitamin K deficiency, which can be prevented by prophylactic vitamin K administration to the mother.
Excreted in breast milk; M/P ratio unknown. Caution due to potential for infant methemoglobinemia or gastrointestinal disturbances.
Isoniazid is excreted into breast milk in concentrations similar to maternal plasma. The milk-to-plasma (M/P) ratio is approximately 1.0. The American Academy of Pediatrics considers it compatible with breastfeeding. However, due to the theoretical risk of hepatotoxicity and peripheral neuropathy in the infant, monitoring of the infant for signs of jaundice, hepatitis, or neuropathy is recommended. The dose to the infant is subtherapeutic (about 0.5-2% of the maternal dose) and is unlikely to cause adverse effects.
No specific dose adjustment recommended; standard doses may be used, but monitor for potassium disturbances due to pregnancy-induced hypervolemia.
Standard dosing of isoniazid (300 mg daily or 900 mg twice weekly) is generally recommended during pregnancy. No dose adjustment is required as pregnancy does not significantly alter the pharmacokinetics of isoniazid. However, due to increased hepatic metabolism in pregnancy, some experts recommend monitoring serum drug levels to ensure therapeutic concentrations, though routine monitoring is not standard. Pyridoxine (25-50 mg daily) should be co-administered to prevent peripheral neuropathy in the mother and fetus.
Monitor for hepatotoxicity, including elevated liver enzymes and bilirubin, especially in the first 3 months of therapy. Administer with food to reduce GI upset. Concurrent use with rifampin may decrease rifampin levels; separate doses by 8-12 hours. Contraindicated in severe renal impairment (Cr Cl < 30 m L/min) due to risk of hypokalemia and salicylate toxicity. Hypersensitivity reactions including fever, rash, and eosinophilia may occur; discontinue if severe.
NYDRAZID (isoniazid) is a first-line antitubercular agent. Always prescribe pyridoxine (vitamin B6) 25-50 mg daily to prevent peripheral neuropathy, especially in patients with risk factors like diabetes, alcoholism, malnutrition, or HIV. Monitor liver function tests closely; hepatotoxicity risk increases with age >35, concurrent use of acetaminophen or other hepatotoxic drugs, and pre-existing liver disease. Slow acetylators (genetic) have higher risk of toxicity. Isoniazid can cause bilateral optic neuritis; monitor for visual symptoms. Drug interactions: increases levels of phenytoin, carbamazepine, and theophylline; reduce doses accordingly. Administer on empty stomach (1 hour before or 2 hours after meals) for optimal absorption. In case of overdose, high-dose pyridoxine is antidote (1 g per gram of isoniazid ingested).
Take this medication with food or milk to prevent stomach upset.,Do not take antacids containing aluminum or magnesium within 3 hours of this medication.,Avoid alcohol while taking this medication due to increased risk of liver damage.,Report any signs of liver problems (yellowing skin or eyes, dark urine, abdominal pain) to your doctor immediately.,Use effective contraception during treatment as this drug may harm an unborn baby.,Do not stop taking this medication without consulting your doctor, even if you feel better.,Keep all appointments for blood tests to monitor liver function and potassium levels.
Take isoniazid on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Do not drink alcohol while taking this medication; combined with alcohol increases risk of severe liver damage.,Take vitamin B6 (pyridoxine) exactly as prescribed to prevent nerve damage.,Report immediately: dark urine, pale stools, yellowing of skin or eyes, nausea/vomiting, abdominal pain, unusual fatigue (liver toxicity signs).,Report numbness, tingling, or burning in hands/feet; vision changes; rash; or fever.,Avoid foods high in tyramine (aged cheese, cured meats, soy products, tap beer) while taking isoniazid; may cause hypertensive crisis.,Take all doses on schedule; do not skip or stop without consulting provider.,Keep all follow-up appointments for blood tests to monitor liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM AMINOSALICYLATE vs NYDRAZID, answered by our medical review team.
POTASSIUM AMINOSALICYLATE is a Antitubercular Agent that works by Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.. NYDRAZID is a Antitubercular Agent that works by Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM AMINOSALICYLATE and NYDRAZID depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM AMINOSALICYLATE is: Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.. The standard adult dose of NYDRAZID is: 300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM AMINOSALICYLATE and NYDRAZID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM AMINOSALICYLATE is classified as Category C. First trimester: Insufficient data; no known human teratogenicity but animal studies inconclusive. Second/third trimester: No documented fetal harm; use only if clearly needed.. NYDRAZID is classified as Category C. Isoniazid (INH) is not associated with major congenital malformations in humans. However, in vivo animal studies have shown embryocidal effects at high doses. The drug is considere. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.